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Abstract
Background: There are many studies in the literature on the association between depression treatment and health
expenditures. However, there is a knowledge gap in examining this relationship taking into account coexisting
chronic conditions among patients with diabetes. We aim to analyze the association between depression treatment
and healthcare expenditures among adults with Type 2 Diabetes Mellitus (T2DM) and newly-diagnosed depression,
with consideration of coexisting chronic physical conditions.
Methods: We used multi-state Medicaid data (2000–2008) and adopted a retrospective longitudinal cohort design.
Medical conditions were identified using diagnosis codes (ICD-9-CM and CPT systems). Healthcare expenditures
were aggregated for each month for 12 months. Types of coexisting chronic physical conditions were hierarchically
grouped into: dominant, concordant, discordant, and both concordant and discordant. Depression treatment
categories were as follows: antidepressants or psychotherapy, both antidepressants and psychotherapy, and no
treatment. We used linear mixed-effects models on log-transformed expenditures (total and T2DM-related) to
examine the relationship between depression treatment and health expenditures. The analyses were conducted on
the overall study population and also on subgroups that had coexisting chronic physical conditions.
Results: Total healthcare expenditures were reduced by treatment with antidepressants (16 % reduction), psychotherapy
(22 %), and both therapy types in combination (28 %) compared to no depression treatment. Treatment with both
antidepressants and psychotherapy was associated with reductions in total healthcare expenditures among all groups
that had a coexisting chronic physical condition.
Conclusions: Among adults with T2DM and chronic conditions, treatment with both antidepressants and
psychotherapy may result in economic benefits.
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Background
It is well appreciated that depression can increase the
medical expenditure of patients with chronic physical
conditions such as type 2 diabetes mellitus or cardiovas-
cular disease. Indeed, individuals with coexisting type 2
diabetes mellitus (T2DM) and depression use more
healthcare services including inpatient care [12], out-
patient care [11, 30], and prescription drug use [11, 30].
These patients’ records also show higher total medical
expenses [6, 11, 12], as well as T2DM-related medical
care expenditures, when compared to individuals with
T2DM and no depression [23]. Indeed, the coexistence
of depression and diabetes in patients is associated with
4.5-fold higher healthcare expenditures compared to pa-
tients without depression [11]. However, successful de-
pression treatment has been associated with lower
subsequent healthcare utilization and expenditures [40].
Randomized clinical trials have studied whether de-
pression treatment delivered in primary care-based col-
laborative care settings among individuals with both
depression and T2DM reduces healthcare expenditures
when compared to usual care, in which referrals to out-
side mental healthcare professionals are given [19, 22,
39]. In collaborative healthcare settings, both depression
and T2DM are managed with the help of coordinated
healthcare teams comprised of primary care physicians,
nurses, and other specialists. For example, the Pathways
Study [22, 39], which included participants with diabetes
and coexisting depression, found lower total healthcare
expenditures at the end of 2-year and 5-year periods in
the intervention group that received a 12 month
stepped-care depression management program when
compared to the control group that received usual care.
In addition, a few observational studies have examined
the association between depression treatment and
healthcare expenditures among individuals with other
chronic conditions. Using administrative claims data,
one study showed that among individuals with dyslipid-
emia, T2DM, and coronary artery disease, existing either
alone or as comorbid conditions, antidepressant medica-
tion adherence improved adherence to coexisting disease
medications and thus reduced one-year healthcare ex-
penditures [18]. In contrast, a study using elderly Medi-
care patient data found that beneficiaries with coexisting
depression and chronic disease who received depression
treatment had higher expenditures compared to patients
not receiving depression treatment [5].
To summarize findings so far, randomized controlled
trials have demonstrated that depression treatment de-
livered in collaborative care settings reduces expendi-
tures among individuals with T2DM and coexisting
depression, while studies using real world observational
data have reported inconsistent findings. However, these
studies were not specific to T2DM patients and also
included special patient populations such as the elderly.
It remains to be established whether depression treat-
ment with antidepressants and psychotherapy, either
alone or in combination, reduces healthcare expendi-
tures among individuals with T2DM. Therefore, the pri-
mary objective of this study was to examine the
association between the depression treatment method
and healthcare expenditures among working age Medic-
aid beneficiaries with T2DM and newly-diagnosed de-
pression. Additionally, to the best of our knowledge the
literature is void on whether this association varies by
coexisting chronic physical conditions. With the major-
ity of adults (88.6 %) with T2DM in the U.S. having at
least one additional chronic condition, and 15 % having
reported four or more comorbid chronic conditions [7],
the presence of comorbid chronic physical conditions
among individuals with T2DM is a norm rather than an
exception. Therefore, it is important to examine whether
the relationship between depression treatment and ex-
penditures varies by the type of coexisting chronic phys-
ical condition. It is particularly important to study this
association in the working age population given that, in
recent years, the prevalence of multiple coexisting
chronic conditions has been increasing among working
age adults [29, 43]. The primary objective of the study is
examine whether the associations between depression
treatment and T2DM-related, as well as total, healthcare
expenditures vary by the type of coexisting chronic phys-
ical condition among working age Medicaid beneficiaries
with T2DM and newly-diagnosed depression.
Methods
Study design
A retrospective longitudinal study with repeated mea-
sures design was used.
Data source
Medicaid Analytic Extract (MAX) files
The MAX files are prepared and produced by the Centers
for Medicare and Medicaid Services. Person-level data
such as eligibility, demographics, managed care enroll-
ment, a utilization summary, and Medicaid payments for
enrollees are provided in the enrollment (“personal sum-
mary”) file. Information on International Classification of
Diseases 9th revision (ICD-9-CM codes) of conditions di-
agnosed, healthcare service utilizations, and charges paid
by Medicaid for the services can be extracted from in-
patient and other therapy files. Information on prescrip-
tion drug use is provided in the pharmacy file. This study
used Medicaid data from 2000–2008 from three states:
New York (NY), Texas (TX), and Illinois (IL). These states
were chosen to capture the diverse geographic and racial/
ethnic populations represented by Medicaid. These states
were among the largest state in terms of the number of
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Medicaid enrollees and include very diverse geographic
and racial/ethnic populations. There have been many
studies using Medicaid data from a few states [35, 49].
Area Health Resource Files (AHRF)
The AHRF contains national county-level health re-
source information on more than 6000 county level vari-
ables and is provided by the U.S. Department of Health
and Human Services (2011) [48]. The Federal Informa-
tion Processing Standard county codes, which are avail-
able both in the AHRF file and the personal summary
file of the MAX data, were used to link the two files.
Identification of the T2DM and newly-diagnosed
depression study cohort
Seven longitudinal cohorts were identified: 2000–02,
2001–03, 2002–04, 2003–05, 2004–06, 2005–07, 2006–08.
The study sample was comprised of working age adults
aged 18–64 years with type 2 diabetes mellitus and at least
one coexisting dominant, concordant, or discordant
chronic physical condition and who were alive, not dually
eligible for Medicare, and continuously enrolled in fee-for-
service Medicaid for at least 24 months (N = 5295). Adults
in the age group 18 and 64 years are defined as working
age individuals. We describe our cohort creation in
detail below.
Medicaid beneficiaries with T2DM
Medicaid enrollees with at least one inpatient visit or two
or more physician outpatient visits which were at least
30 days apart, with a primary or secondary diagnosis of
ICD-9-CM codes 250.x0 or 250.x2 during a calendar year,
were identified as having T2DM. Medicaid beneficiaries
with T2DM who had a diagnosis of depression or anti-
depressant medication use during the calendar year of
their T2DM diagnosis as per our identification procedure
were excluded.
Medicaid beneficiaries with newly-diagnosed depression
The eligible study population was followed into the
subsequent calendar year to identify cases of newly-
diagnosed depression. Enrollees with at least one out-
patient physician visit or an inpatient admission with a
primary or secondary diagnosis of depression in the fol-
lowing calendar year were classified as having newly-
diagnosed depression [42]. Depression was identified
using ICD-9-CM codes: 296.2 (major depressive dis-
order, single episode), 296.3 (major depressive disorder,
recurrent episode), 311 (depression not elsewhere classi-
fied), 309.1 (prolonged depressive reaction), 300.4 (neur-
otic depression) and 298.0 (depressive type psychosis).
These ICD-9-CM codes are extensively used by health
plans to identify depression and have also been used in
previous studies on depression in Medicaid enrollees
[36, 37, 44]. Those with no newly-diagnosed depression
were excluded from the study cohort. The first observed
date of outpatient visit or inpatient discharge with a
diagnosis of depression was the “index date”; enrollees had
to be free of a depression diagnosis or antidepressant
medication prescription 365 days prior to the index date.
Although other studies have used 120 day depression-free
periods to define newly-diagnosed depression [46], our
365 day look-back period was used with the intent to
minimize misclassification of an episodic manifestation of
chronic depression (where depression symptoms last for
two or more years) as newly-diagnosed depression.
Additional exclusion criteria were: (1) not having a
diagnosis of at least one chronic physical condition
(identified by ICD-9-CM codes included in Appendix) in
the baseline period; (2) no continuous fee-for-service
Medicaid eligibility; (3) enrollment in Medicare at any
point during the observation period; (4) dying during
the study period; and (5) not using inpatient or out-
patient Medicaid services during the study period. We
excluded patients who did not use inpatient or out-
patient Medicaid services because we cannot capture
type of depression treatment, coexisting conditions, and
healthcare expenditure for these individuals. We in-
cluded only those enrolled in fee-for-service Medicaid
program because healthcare experience of adults who
are not enrolled in fee-for-service cannot be captured.
We excluded patients who died during the study period
as they have a shorter observation time and healthcare
expenditures peak during the time period before death.
Therefore, our estimates could be underestimated.
Dependent variables
Total healthcare expenditures
Total healthcare expenditure per person included in the
study cohort was defined as the total dollar amount that
Medicaid paid for inpatient, outpatient, and pharmacy
claims.
T2DM-related healthcare expenditures
T2DM-related healthcare expenditure per person in-
cluded in the study cohort was defined as the total dollar
amount that Medicaid paid for inpatient and outpatient
claims with a diagnosis of T2DM. The T2DM-related
healthcare expenditures were also identified on a monthly
basis during the 12 month follow-up period.
The total and T2DM-related healthcare expenditures
were adjusted by the medical component of the
Consumer Price Index (CPI) and are expressed in 2008
constant dollars. After assessing the skewness and kur-
tosis properties and linearity through qq-plots, the ex-
penditure variables were log transformed and used as
dependent variables.
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Independent variables
The independent variables were chosen based on a be-
havioral model of factors that influence the use of health
services known as the Anderson Behavioral Model
(ABM) [2]. The ABM posits that utilization of health
services varies as a function of (1) each individual’s
unique predisposition for using services (predisposing
factors); (2) the means available to each individual for
obtaining services (enabling factors); (3) each individual’s
level of need; (4) personal health practices; and (5) the
external environment. Based on the ABM, we used a
breadth of independent variables in our study. Here we
provide detailed information on several variables associ-
ated with need, followed by additional independent vari-
ables congruent with the ABM.
Key independent variables: depression treatment during the
acute phase (need factor)
The first four months following newly-diagnosed depres-
sion is known as the acute phase of depression treat-
ment [47]. The initial treatment choice may influence
the effectiveness of depression treatment and therefore
may also be associated with healthcare expenditures over
time. Single-modality depression treatment with either
antidepressants or psychotherapy could be used during
the acute phase, as could combination treatment.
Antidepressant use
The national drug codes available in the prescription
drug use files of MAX data were used to identify the dif-
ferent classes of antidepressant drugs: selective serotonin
reuptake inhibitors, selective norepinephrine reuptake
inhibitors, tricyclic antidepressants, monoamine oxidase
inhibitors and other (mirtazapine and bupropion).
Psychotherapy Use: The use of psychotherapy was identi-
fied with Current Procedural Terminology (CPT) codes.
The following psychotherapy types were used: (1) psycho-
therapy diagnostic interview (90801, 90802); (2) individual
psychotherapy [individual psychotherapy 20–30 min
(90804, 90816, 90805, 90817), 45–50 min (90806, 90818,
90807, 90819), 75–80 min (90808, 90821, 90809, 90822),
interactive individual psychotherapy 20–30 min (90810,
90823, 90811, 90824), 45–50 min (90812, 90826, 90813,
90827), 75–80 min (90814, 90828, 90815, 90829)]; (3)
other psychotherapy [family psychotherapy (90846, 90847,
90849), group psychotherapy (90853), interactive group
psychotherapy (90857)] [16].
Depression treatment in the acute phase was catego-
rized as treatment with: (1) antidepressants: these
individuals received at least one prescription for antide-
pressants, but no psychotherapy visits; (2) psychother-
apy: those who received at least one psychotherapy
office visit but no prescription for antidepressant drugs;
(3) both antidepressants and psychotherapy: those who
received a minimum of one prescription for antidepres-
sants and one psychotherapy visit; and (4) no treatment:
these individuals did not receive a prescription for anti-
depressants or psychotherapy office visits.
Coexisting chronic physical condition types (need factor)
As other physical conditions coexisting with T2DM
often impact the medical care, self-management, and
healthcare outcomes of an individual with T2DM, Piette
and Kerr [34] developed a framework that classified
coexisting conditions among individuals with T2DM into
categories based on similarities and differences from
T2DM pathophysiology and management. The cate-
gories of conditions that might coexist with T2DM were
defined as: dominant (conditions whose severity eclipses
all other conditions’ management plans, such as meta-
static cancer), concordant (conditions that overlap with
T2DM in their pathophysiology and management plans
such as cardiovascular diseases), or discordant (conditions
with unrelated pathophysiology or management plans
such as musculoskeletal disorders) [34].
Following this framework, it is likely that the presence
of coexisting conditions among individuals with T2DM
and newly-diagnosed depression may affect depression
management and the response to depression treatment.
Therefore, based on this theoretical framework, forty-
four different coexisting chronic physical condition types
(Appendix) were identified. A hierarchical classification
was followed [18], and dominant conditions were given
priority because they often take precedence over the
management of other health conditions. Only among
those without dominant conditions, concordant and
discordant conditions were identified. The types of co-
existing chronic physical conditions were classified as:
1) dominant conditions; 2) concordant; 3) discordant;
and 4) both concordant and discordant.
Other independent variables
Predisposing Factors: The included variables were based
on demographics (gender, age, race/ethnicity [Whites,
African Americans, Hispanics or other races]). Enabling
Factors: Using Medicaid eligibility status, the enabling
factors included were: eligibility due to poverty (yes/no),
medical needs (yes/no) and waiver (yes/no). Need
Factors: These included other mental health conditions
such as bipolar disorder, schizophrenia, post-traumatic
stress disorder, and alcohol and drug abuse. Personal
Health Practices: Healthcare-seeking behaviors were used
as a measure for personal health practices and included
baseline healthcare utilization characteristics such as
number of emergency room visits during the 180 days
prior to the index date, inpatient hospitalization, number
of oral antidiabetic medication classes and insulin use as
identified by NDC codes, presence of polypharmacy
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identified by use of six or more drug classes in the 90 days
prior to the index date, number of outpatient visits mea-
sured in quartiles and total baseline healthcare ex-
penditures. External Environment: External environment
variables included state of residence, community level
healthcare infrastructure (presence of a community men-
tal health clinic (CMHC) and a federally qualified health
clinic (FQHC) in a county, whether county of residence
was designated as a Health Professional Shortage area
(HPSA), and density of social workers in a county), and
community level social determinants of health variables
(urban/rural status of a county, median income in the
county, indicators for whether the percentage below pov-
erty level and percentage with college education in the
county were different than national averages based on
U.S. census estimates). Other variables: After depression
treatment response is achieved during the acute phase,
treatment for depression may be continued for another 4
to 9 months in the continuation phase. Therefore, it may
be plausible that some individuals received depression
treatment with antidepressants and/or psychotherapy dur-
ing the entire length of follow-up, whereas some people
had a shorter treatment period. To control for such vari-
ation, the statistical models additionally controlled for
Antidepressant treatment at each month of follow-up: This
was defined as a dichotomous (yes/no) variable, which
indicated whether an individual received an antidepressant
prescription during each month of the follow-up; Psy-
chotherapy treatment at each month of follow-up: A
categorical (yes/no) variable that indicated whether an
individual received outpatient psychotherapy during
each month of the follow-up; Year of observation: As
data from multiple years forming seven different panels
were used (2000–2002, 2001–2003, 2002–2004, 2003–
2005, 2004–2006, 2005–2007, 2006–2008), a variable indi-
cating which particular cohort the observation belonged
to was also included.
Statistical analyses
We provide descriptive statistics, including frequency,
mean, standard errors, and chi-square statistics. As health-
care expenditures were aggregated for each month of
follow-up, 12 observations were available for each individ-
ual. Due to repeated measures of healthcare expenditures,
the observations were not independent. Because standard
regression techniques assume that individual observations
are independent, they cannot be applied to data with re-
peated measures. Therefore, the multivariable analyses
consisted of linear mixed effects models which accounted
for correlated error terms of observations from the same
person. More specifically, we adjusted for both random ef-
fects (a random intercept) and fixed effects including time
in months, depression Treatment, predisposing factors
(gender, age, race/ethnicity), need factors (other mental
health conditions, coexisting chronic physical condition
type), enabling factors (Medicaid eligibility -poverty, med-
ical need, waiver), personal health practices (number of
ER and outpatient visits, inpatient hospitalization, number
of OAD classes, insulin use and polypharmacy), external
environment characteristics (whether county of residence
had a CMHC, FQHC, was HPSA for mental health, dens-
ity of social workers, rural/urban status of county, median
income in the county, whether percent below poverty level
and percent with college education were greater than the
national average), and other variables (antidepressant
treatment at each month of follow-up, psychotherapy
treatment at each month of follow-up and year of observa-
tion). Separate linear mixed model regressions on log of
expenditures for each coexisting chronic physical condi-
tion type were conducted to examine whether the
association between depression treatment and total and
T2DM-related healthcare expenditures varied by comor-
bid condition type.
Adjusting for observed selection bias
Depression treatment is a choice variable and character-
istics of the study population can influence this choice.
To account for such observed differences, the inverse
probability of treatment weighting (IPTW) was used.
We used a logistic regression model to generate the
estimated probability of treatment (i.e. propensity). The
IPTW gives weight to each individual based on the
inverse of their propensity to use a particular type of de-
pression treatment. This helps to balance the probability
of treatment across the treatment groups. In order to ac-
count for group size differences of the treatment groups,
the weights were further stabilized by dividing them with
the sample size of each group.
All analyses were conducted using Statistical Analysis
Software (SAS 9.3).
Results
In the study population (N = 5295), 36.3 % were aged
45–54 years, 38.5 % were between 55–64 years of age,
and 25.2 % were aged 18–44 years; 67.3 % were female
and 32.7 % were male; 26.8 % were white, 30.1 % were
African American, and 43 % belonged to another race;
the majority (89.1 %) lived in metro areas. 16.8 % lived
in counties that were designated as shortage areas for
mental health professionals and 51.1 % lived in counties
without a community mental health clinic. A description
of the study population is presented in Table 1.
In the study population, 14.2 % had a coexisting chronic
dominant condition, 27.3 % had a concordant condition,
15.8 % had a discordant condition, and 42.8 % had both a
concordant and discordant condition (see Methods for
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Table 1 Description of the study population by coexisting chronic physical condition type among medicaid beneficiaries with type
2 diabetes mellitus and newly diagnosed depression. Multi-state medicaid claims database – 2000–2008
All Dominant Concordant only Discordant only Both concordant & discordant Sig
N % N % N % N % N %
All 5295 753 14.2 1444 27.3 834 15.8 2264 42.8 ***
Predisposing factors
Age
18–44 1335 25.2 122 9.1 426 31.9 256 19.2 531 39.8
45–54 1921 36.3 277 14.4 457 23.8 317 16.5 870 45.3
55–64 2039 38.5 354 17.4 561 27.5 261 12.8 863 42.3
Sex ***
Female 3565 67.3 437 12.3 949 26.6 613 17.2 1566 43.9
Male 1730 32.7 316 18.3 495 28.6 221 12.8 698 40.3
Race **
White 1420 26.8 203 14.3 369 26.0 251 17.7 597 42.0
AA 1596 30.1 240 15.0 396 24.8 250 15.7 710 44.5
Other 2279 43.0 310 13.6 679 29.8 333 14.6 957 42.0
Need factor
Other mental health conditions ***
Yes 1877 35.4 349 18.6 476 25.4 294 15.7 758 40.4
No 3418 64.6 404 11.8 968 28.3 540 15.8 1506 44.1
Enabling factors
Medicaid eligibility - poverty **
Yes 4620 87.3 1237 26.8 708 15.3 2014 43.6 661 14.3
No 675 12.7 207 30.7 126 18.7 250 37.0 92 13.6
Medicaid eligibility - Medical Need *
Yes 638 12.0 181 28.4 108 16.9 238 37.3 111 17.4
No 4657 88.0 1263 27.1 726 15.6 2026 43.5 642 13.8
Medicaid eligibility - Waiver
Yes 300 5.7 89 29.7 60 20.0 114 38.0 37 12.3
No 4995 94.3 1355 27.1 774 15.5 2150 43.0 716 14.3
Personal health practices
Oral Antidiabetic Drugs (OADs) ***
1 1508 28.5 171 11.3 422 28.0 272 18.0 643 42.6
2 1238 23.4 144 11.6 353 28.5 214 17.3 527 42.6
3+ 450 8.5 38 8.4 156 34.7 63 14.0 193 42.9
None 2099 39.6 400 19.1 513 24.4 285 13.6 901 42.9
Insulin Use ***
Yes 1827 34.5 277 15.2 512 28.0 148 8.1 890 48.7
No 3468 65.5 476 13.7 932 26.9 686 19.8 1374 39.6
Polypharmacy ***
Yes 1915 36.2 293 15.3 345 18.0 295 15.4 982 51.3
No 3380 63.8 460 13.6 1099 32.5 539 15.9 1282 37.9
Inpatient hospitalization ***
Yes 2604 49.2 534 20.5 532 20.4 232 8.9 1306 50.2
No 2691 50.8 219 8.1 912 33.9 602 22.4 958 35.6
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Table 1 Description of the study population by coexisting chronic physical condition type among medicaid beneficiaries with type
2 diabetes mellitus and newly diagnosed depression. Multi-state medicaid claims database – 2000–2008 (Continued)
Outpatient visits ***
1st quartile 1392 26.3 85 6.1 588 42.2 294 21.1 425 30.5
2nd quartile 1221 23.1 139 11.4 352 28.8 215 17.6 515 42.2
3rd quartile 1352 25.5 227 16.8 282 20.9 180 13.3 663 49.0
4th quartile 1330 25.1 302 22.7 222 16.7 145 10.9 661 49.7
Mean ± SE Mean ± SE Mean ± SE Mean ± SE Mean ± SE
Number of T2DM-related office visits 6.93 ± 0.13 7.98 ± 0.29 6.51 ± 0.29 5.44 ± 0.21 7.40 ± 0.19
Number of ER visits 1.18 ± 0.03 1.65 ± 0.11 0.66 ± 0.04 0.78 ± 0.05 1.51 ± 0.05
External environment
State ***
Illinois 1502 28.4 211 14.0 379 25.2 256 17.0 656 43.7
New York 2550 48.2 402 15.8 725 28.4 405 15.9 1018 39.9
Texas 1243 23.5 140 11.3 340 27.4 173 13.9 590 47.5
HPSA- mental health care *
Yes 4405 83.2 651 14.8 1209 27.4 679 15.4 1866 42.4
No 890 16.8 102 11.5 235 26.4 155 17.4 398 44.7
Metro **
Yes 4719 89.1 698 14.8 1291 27.4 730 15.5 2000 42.4
No 576 10.9 55 9.5 153 26.6 104 18.1 264 45.8
CMHC
Yes 2590 48.9 376 14.5 702 27.1 393 15.2 1119 43.2
No 2705 51.1 377 13.9 742 27.4 441 16.3 1145 42.3
FQHC **
Yes 4365 82.4 651 14.9 1199 27.5 674 15.4 1841 42.2
No 930 17.6 102 11.0 245 26.3 160 17.2 423 45.5
Median income **
1st quartile 1312 24.8 145 11.1 365 27.8 204 15.5 598 45.6
2nd quartile 1415 26.7 199 14.1 378 26.7 246 17.4 592 41.8
3rd quartile 1235 23.3 182 14.7 345 27.9 190 15.4 518 41.9
4th quartile 1333 25.2 227 17.0 356 26.7 194 14.6 556 41.7
% with GT 4 years college education > 16%a **
Yes 4399 83.1 656 14.9 1197 27.2 704 16.0 1842 41.9
No 896 16.9 97 10.8 247 27.6 130 14.5 422 47.1
% below poverty level GT 11.1%b 753 1444 834 2264
Yes 4692 88.6 675 14.4 1284 27.4 732 15.6 2001 42.6
No 603 11.4 78 12.9 160 26.5 102 16.9 263 43.6
Mean ± SE Mean ± SE Mean ± SE Mean ± SE Mean ± SE
Density of Social Workers 3.01 ± 0.02 3.27 ± 0.06 3.02 ± 0.04 3.02 ± 0.06 2.91 ± 0.04
Note: Study sample was comprised of adults with type 2 diabetes mellitus aged 18–64 years with at least one coexisting dominant, concordant, or discordant
chronic physical condition and who were alive, not dually eligible for Medicare, and continuously enrolled in fee-for-service Medicaid for at least 24 months
(N = 5295); includes Medicaid data from three states: Illinois, Texas, New York
Asterisks (*) represent significant differences in study population characteristics and coexisting chronic physical condition categories (e.g. Dominant, Concordant
Only, Discordant Only, and Both Concordant and Discordant), derived from chi-square statistics
***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05
a16 % cutoff was chosen based on 2000 Census Education attainment results
b11.1 % cutoff was chosen based on 1999 Census Poverty in people aged 18–64 years results
HPSA Health Professional Shortage Area, CMHC Community Mental Health Clinic, FQHC Federally Qualified Health Clinic, GT Greater Than
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condition definitions). All individual baseline characteristics
and the majority of the county level characteristics differed
significantly among the comorbid chronic condition
type. For example, a greater proportion of individuals
with dominant conditions were older (17.4 % were aged
55–64 years vs 9.1 % in the 18–44 year age group),
male (18.3 % vs 12.3 % female), had other mental health
conditions in addition to newly-diagnosed depression
(18.6 % vs 11.6 % with no other mental health condi-
tion), inpatient hospitalization (20.5 % vs 8.1 % for
those with no inpatient care), and had a higher number
of outpatient visits (22.7 % in the 4th vs 6.1 % in the
1st quartile). Table 1 also presents a description of the
study population by type of coexisting chronic physical
condition and contains additional features including
Medicaid eligibility status and median income.
During the acute phase, 27.3 % of the study population
had treatment with antidepressants, 18.1 % had treat-
ment with psychotherapy, 11.4 % had treatment with
both antidepressants and psychotherapy, and 43.2 % had
no depression treatment. Unadjusted chi-square analyses
revealed that depression treatment during the acute
phase varied significantly (P-value <0.001) among the
coexisting chronic physical condition subgroups. For ex-
ample, treatment with both antidepressants and psycho-
therapy was received by 12.6 % of the study population
with dominant conditions, 11.2 % with concordant con-
ditions, 10.7 % with discordant conditions, and 11.4 %
with both concordant and discordant conditions. These
data are not presented in tabular form.
The mean total and T2DM-related healthcare expendi-
tures for the 12 month period after depression diagnosis
were $30,590 and $13,642, respectively, for the group
given antidepressants, $35,099 and $15,654 for those
treated with psychotherapy, $33,032 and $15,726 for the
group treated with both antidepressants and psycho-
therapy, and $34,041 and $14,801 for those receiving no
depression treatment. The mean monthly total and
T2DM-related expenditures across all depression treat-
ment categories decreased over time in both the overall
population as well as within each coexisting chronic
physical condition subgroup.
Table 2 presents the results of linear mixed model re-
gression analyses which revealed that, compared to no
depression treatment, all other treatment types were asso-
ciated with a reduction in total healthcare expenditures.
When compared to no depression treatment, depression
treatment with only antidepressants was associated with
16 % (95 % CI: 10 %–23 %) reduction in total healthcare
expenditures, treatment with only psychotherapy was as-
sociated with 22 % (95 % CI: 14 %–29 %) reduction in total
healthcare expenditures and treatment with both antide-
pressants and psychotherapy was associated with 28 %
(95 % CI: 19 %–36 %) reductions in total healthcare ex-
penditures. Treatment with psychotherapy and both anti-
depressants and psychotherapy was associated with 28
and 18 % reduction in T2DM-related expenditures as
compared to no depression treatment.
The IPTW-adjusted association between depression
treatment categories during the acute phase and healthcare
expenditures varied by coexisting chronic physical condi-
tion type (Table 3). Treatment with only psychotherapy was
associated with significant reductions in total healthcare ex-
penditures and T2DM related Expenditures among those
with dominant conditions and among those with both con-
cordant and discordant conditions. Treatment with both
antidepressants and psychotherapy was associated with re-
ductions in total healthcare expenditures among all types of
coexisting chronic physical condition groups.
Discussion
The study findings indicate that depression treatment is
associated with reductions in total healthcare expenditures
as compared to no depression treatment. Randomized
clinical trials examining the effectiveness of depression
Table 2 IPTW adjusted association between depression treatment and healthcare expenditures, among medicaid beneficiaries with
type 2 diabetes mellitus and newly-diagnosed depression multi-state medicaid claims database – 2000 – 2008
ALL expenditures T2DM-related expenditures
Depression treatment Change 95 % CI Sig Change 95 % CI Sig
Only antidepressants −0.16 −0.23 −0.10 *** −0.10 −0.18 0.00
Only psychotherapy −0.22 −0.29 −0.14 *** −0.28 −0.36 −0.19 ***
Antidepressants and psychotherapy −0.28 −0.36 −0.19 *** −0.18 −0.29 −0.06 **
Reference Group: No Depression Treatment
Note: Study sample was comprised of adults with type 2 diabetes mellitus aged 18–64 years with at least one coexisting dominant, concordant, or discordant
chronic physical condition and who were alive, not dually eligible for Medicare, and continuously enrolled in fee-for-service Medicaid for at least 24 months
(N = 5295); includes Medicaid data from three states: Illinois, Texas, New York
All healthcare expenditures included inpatient, outpatient, and prescription drug-related expenditures; T2DM- related expenditures included inpatient and
outpatient expenditures due to T2DM-related diagnosis. The expenditures were log transformed
Asterisks indicate statistical significance and are based on mixed effects models; no antidepressant treatment is the reference group for dependent variable.
***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05
T2DM Type 2 Diabetes Mellitus; depression: Major Depressive Disorder, IPTW Inverse Probability Treatment Weights, SE Standard Error
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treatment with antidepressants and/or psychotherapy in
the T2DM patient population with coexisting depression
have found that antidepressants reduce the symptoms of
depression [1, 15, 24–26, 28, 32, 33]. Moreover, psycho-
therapy (e.g. cognitive behavioral therapy) has also been
shown to be effective in providing relief from depression
in these patients [13, 27, 41]. Therefore, depression treat-
ment may reduce healthcare expenditures by lowering
mental health-related expenditures. Additionally, individ-
uals with depression have been shown to have high utiliza-
tions of healthcare services [20, 38], and coexisting
depression can worsen other medical conditions by ad-
versely affecting medication adherence [14] and self-care
regimens [21]. Thus, healthcare expenditures may be re-
duced when depression is effectively treated and patients
decrease their healthcare utilization, improve their adher-
ence to other chronic disease medications, and administer
better self-care regimens.
Our results show that depression treatment modalities
are associated with reductions in T2DM-related healthcare
expenditures, a finding which is comparable to limited
evidence from previous research. For example, Lustman
et al. showed that among 51 individuals with T2DM
and depression, 10 weeks of cognitive behavioral ther-
apy was significantly associated with reduced glycated
hemoglobin (HbA1c) levels, an indicator of lower blood
sugar levels and diabetes management, in the interven-
tion group at 6 month after follow-up (intervention vs
control: 9.5 % vs 10.9 %; P = 0.03). Evidence from ran-
domized controlled trials of collaborative care, which
often includes depression treatment with antidepressants
as well as psychotherapy (either initiated together or in
a stepped care approach based on response to initial
treatment), has shown significant reductions in HbA1c
levels in the intervention group compared to the con-
trol group [3]. These studies support our findings that
depression treatment modalities with psychotherapy
can reduce T2DM-related expenditures. Our study fo-
cused on patients with T2DM and followed them for
depression and its treatment. There are debates on the
causal pathway of diabetes and depression indicating
the possibility that there is reverse causality between
diabetes and depression. The current study did not ex-
plore such issues.
Table 3 IPTW adjusted association between depression treatment and healthcare expenditures stratified by coexisting condition
type. Among medicaid beneficiaries with type 2 diabetes mellitus and newly diagnosed depression. Multi-state medicaid claims
database – 2000–2008
ALL expenditures T2DM-related expenditures
Depression treatment categories Change 95 % CI Sig Change 95 % CI Sig
Dominant
Only antidepressants −0.23 −0.41 0.01 −0.23 −0.44 0.06
Only psychotherapy −0.48 −0.59 −0.34 *** −0.41 −0.55 −0.23 ***
Antidepressants and Psychotherapy −0.41 −0.57 −0.19 ** −0.24 −0.48 0.1
Concordant ONLY
Only antidepressants −0.21 −0.33 −0.08 ** −0.05 −0.22 0.16
Only psychotherapy −0.11 −0.26 0.06 −0.19 −0.36 0.03
Antidepressants and Psychotherapy −0.23 −0.38 −0.04 * −0.27 −0.44 −0.06 *
Discordant only
Only antidepressants −0.18 −0.31 −0.02 * −0.09 −0.26 0.13
Only psychotherapy −0.09 −0.29 0.18 −0.1 −0.33 0.2
Antidepressants and Psychotherapy −0.29 −0.45 −0.08 * −0.1 −0.35 0.23
Both concordant & discordant
Only antidepressants −0.1 −0.2 0.01 −0.1 −0.23 0.06
Only psychotherapy −0.21 −0.31 −0.09 *** −0.34 −0.45 −0.19 ***
Antidepressants and Psychotherapy −0.27 −0.38 −0.15 *** −0.1 −0.28 0.14
Reference Group: No Depression Treatment
Note: Study sample was comprised of adults with type 2 diabetes mellitus aged 18–64 years with at least one coexisting dominant, concordant, or discordant
chronic physical condition and who were alive, not dually eligible for Medicare, and continuously enrolled in fee-for-service Medicaid for at least 24 months
(N = 5295); includes Medicaid data from three states: Illinois, Texas, New York
All healthcare expenditures included inpatient, outpatient and prescription drug-related expenditures; T2DM-related expenditures included inpatient and
outpatient expenditures due to T2DM-related diagnosis. The expenditures were log transformed
Asterisks indicate statistical significance and are based on mixed effects models; ***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05
T2DM Type 2 Diabetes Mellitus; depression: Major Depressive Disorder; IPTW Inverse Probability Treatment Weights, SE Standard Error
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Across all coexisting condition types, depression treat-
ment with both antidepressants and psychotherapy was
associated with reduced total healthcare expenditures.
Several studies, including multiple randomized clinical
trials [4, 10, 17] and meta-analyses [8, 9] have shown
that, among individuals with depression, combined treat-
ment with both pharmacotherapy and psychotherapy
significantly reduced depression symptoms and dropout
rates. Treatment with both antidepressants and psycho-
therapy has also been shown to have long term benefits
including preventing relapse and increasing depression
treatment adherence [31, 45]. Therefore, by improving
depression-related outcomes, treatment with both anti-
depressants and psychotherapy may help to reduce total
healthcare expenditures.
Interestingly, unlike our finding that treatment with
both antidepressants and psychotherapy was effective
at decreasing total healthcare expenditures in each co-
morbid patient population, other depression treatment
categories were not as uniformly associated with reduc-
tions in healthcare expenditures. For individuals with
either concordant or discordant conditions, antidepres-
sant treatment alone reduced total healthcare expendi-
tures. Depression treatment with only psychotherapy
reduced total and T2DM-related healthcare expendi-
tures among those with a high burden of coexisting
conditions, such as those with dominant conditions,
and also individuals with both concordant and discord-
ant conditions. These results indicate that the choice of
treatment needs to be prioritized based on the type of
coexisting chronic physical condition and should be
considered in addition to the preferred treatment choice
of the physician or patient.
The study findings have important implications in the
context of new payment models such as “bundled pay-
ment”, where providers or facilities are paid a single
lump-sum payment for all services in relation to treating
a condition or providing a treatment. The results of this
study indicate that certain depression treatment types
are ineffective in reducing healthcare expenditures. For
example, healthcare expenditures were not reduced by
depression treatment with only antidepressants in the
presence of dominant conditions. Therefore, among in-
dividuals with T2DM and coexisting dominant condi-
tions, healthcare systems should not expect economic
benefits from initiating treatment for newly-diagnosed
depression with antidepressants under bundled payment
systems. Our results also have implications for “bench-
marking” approaches used by Accountable Care Organiza-
tions (ACOs), where expenditure patterns of beneficiaries
in the past three years are used to set expenditure “bench-
marks” based on risk adjustment models. Our analyses in-
dicate that total healthcare expenditures among Medicaid
beneficiaries with T2DM, newly-diagnosed depression,
and coexisting conditions may vary both by the coexisting
condition type and the method of depression treatment
received. Therefore, while setting benchmarks for this pa-
tient population, risk adjustments for coexisting condition
type and depression treatment modality should be taken
into consideration.
There are several strengths of our study, some of
which are unprecedented. First, Medicaid claims data
spanning multiple years from three states were used in
this study, which allowed us to efficiently follow a
large cohort of patients for a long period of time across a
variety of providers. Second, the study included adults
with multiple comorbid conditions, and this patient
population is often ignored in clinical trials of depres-
sion treatment. Third, the economic consequences of
depression treatment were observed in real world set-
tings instead of the controlled environment of clinical
trials. The use of a repeated measures design allowed
us to study the association between depression treat-
ment and healthcare expenditure over time, instead of
aggregating expenditures at the end of follow-up. To
the best of the authors’ knowledge, such a design has
not yet been adopted by any other study in this area.
Fourth, since the association between depression treat-
ments and healthcare expenditures were adjusted for
inverse probability treatment weights, selection bias
due to differences in observed characteristics in the de-
pression treatment groups could be controlled in the
analyses.
However, as a population-based study using Medicaid
and administrative claims data, our study shares the
limitations often found in observational studies. As ad-
ministrative claims data can only identify diseases through
diagnosis codes, our study could have potentially underesti-
mated newly-diagnosed depression owing to undiagnosed
depression and under-coding of depression. Indeed,
identifying depression is one of the more difficult prob-
lems in administrative data research and perfection
may not be attainable. However, the use of diagnosis
codes recommended by HEDIS by health plans in order
to identify depression claims offers a particularly at-
tractive alternative to the complications associated with
prospective surveys using medical record data. Add-
itionally, T2DM and the coexisting chronic physical
condition types were also identified using diagnosis
codes in medical claims. Incomplete or erroneous records
submitted by healthcare providers, limited clinical detail
in the ICD-9-CM codes, and inaccurate demographic
information might limit the accuracy of administrative
data. The duration of T2DM and the physical comorbid
chronic conditions were not available and could not be
adjusted for in regression analyses. Further, the treat-
ment choices are likely to be partially determined by
the severity of the disease in this observational study.
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Pharmacotherapy may be prescribed in severe cases of
depression and the effect of pharmacotherapy on
expenditures may partially reflect severity of the illness.
Although we controlled for selection bias in observed
variables through an IPTW adjustment, a number of
unmeasured factors such as patient preferences could
influence both treatment choices and treatment outcome.
Finally, the study included fee-for-service Medicaid
beneficiaries enrolled in three states, and the results
might not be fully generalizable to the entire Medicaid
population.
Conclusion
Among working age adults with T2DM, a comorbid
chronic physical condition, and newly diagnosed depres-
sion, depression treatment can produce cost-savings to
Medicaid. Treating depression with antidepressants and
psychotherapy combined may be the best method to
achieve consistent reductions in expenditures across all
types of coexisting chronic physical conditions. For specific
modalities of depression treatment (e.g. antidepressant or
psychotherapy administered singly), cost-reductions will
depend on the coexisting chronic physical condition type.
Table 4 ICD-9-CM codes for identifying coexisting chronic physical condition type. We provide the list of ICD-9-CM codes for
identifying coexisting chronic physical condition type
Conditions ICD-9-CM codes
Concordant Conditions
Coronary Artery Disease 410,4100,4101,4102,4103,4104,4105,4106,4107,4108,4109,411,4110,4111,4118,41181,
41189,412,413,4130,4131,4139,414,4140,41400,41401,41402,41403,41404,41405, 4141,
41410,41411, 41419,4148,4149
Congestive Heart Failure 40201,40211,40291,40401,40411,40491,428,4280,4281,4289
Arrhythmia 423,4230,4231,4232,4238,4239,42731
Stroke 431,43301,43311,43321,43331,43381,43391,43401,43411,43491,435,4350,4351,4352,
4353,4358,4359,438,4380,4381,43811,43812,4382,4383,4384,4385,43850,4385,43852,
43853,4388,43881, 43882,43889,4389
Peripheral Vascular Disease 2507,4402,44020,44021,44022,44023,44024,44029,4408,4409,
4422,4423,443,4430, 4431,
4438,44381, 44389,4439,44422,44481
Peripheral Vascular Disease-gangrene 7854
Renal 40311,40391,40412,40413,40492,40493, 585,586,587, 2741,27410,27411,27419,40310,
40390,40410,40411,40490,40491, 581,5810,5811,5812,5813,5818,5819, 582,5820,5821,
5822,5824,5828,58281,58289,5829,583,5830,5831,5832,5834,5836, 5837,
5838,58381,58389,5839,
5900,59000,59001,5936,5939, 75312,75313,75314
Chronic Renal Failure
Chronic Pathophysiology
Diabetic Nephropathy 2504,25040,25041,25042,25043
Acute Renal Failure and Disease 40300,40301,40400,40401,40402,40403,40501,4533,584,5845,5846,5847,5848,5849,
580,5800,5804,5808,58081,58089,5809,5901,59010,59011,5902,5903,5908,59080,
59081,59381,866,8660,86600,86601,86602,86603,8661,86610,86611,86612,86613
Retinopathy (excludes advanced retinopathy, blindness) 3620,36201,25050,25051,25052,25053
Ulcer 700,68110,68111,6827,7071,73076,73077
Other Diabetes Related Complications 25002,25003,25010,25011,25012,25013,25020,25021,25022,25023,25030,25031,
25032,25033
Uncontrolled Diabetes
Short Term Diabetes
Discordant Conditions
Gastro Intestinal Tract Related Disorders: 5301,5302,5303,53081,531,532,533,534,555,556,56211,56213,574, 575,576,070
GERD/Esophagitis
Peptic ulcers
Inflammatory Bowel Disease
Diverticulitis
Gall bladder disease and stone
Viral hepatitis
Appendix
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Gastropareis 5363
AIDS 042
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